L3VLUP
ProSign in

GEHC · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GEHCJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GEHC
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterGEHCJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 20221 holders, $371m35 holders, $27.6bn
Q1 202313 holders, $8.0bn42 holders, $24.5bn
Q2 202321 holders, $8.7bn38 holders, $25.0bn
Q3 202314 holders, $6.6bn37 holders, $18.9bn
Q4 202313 holders, $7.3bn31 holders, $19.0bn
Q1 202417 holders, $9.7bn32 holders, $19.7bn
Q2 202417 holders, $8.0bn35 holders, $20.4bn
Q3 202420 holders, $10.7bn28 holders, $22.3bn
Q4 202418 holders, $8.8bn37 holders, $20.4bn
Q1 202518 holders, $8.4bn32 holders, $20.5bn
Q2 202522 holders, $7.2bn31 holders, $18.4bn
Q3 202514 holders, $6.3bn32 holders, $23.7bn
Q4 202513 holders, $8.1bn29 holders, $27.8bn
Q1 202611 holders, $6.3bn34 holders, $35.6bn
Q2 20269 holders, $4.9bn33 holders, $39.1bn
GEHC

Ge Healthcare Technologies I

Holders
22
Reported value
$7.2bn
Buyers
15
Sellers
6

Breadth +9 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GEHC (12)

Balyasny Asset Management LLC, Citadel Advisors LLC, D1 Capital Partners LP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Jane Street Group LLC, Moore Capital Management LP, Steadfast Capital Management LP, Trian Fund Management LP

Only JNJ (21)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Caxton Associates LLP, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →